Efficacy and Safety of Brexpiprazole in Agitation Associated with Dementia in Alzheimer's Disease: A Systematic Review and Meta‐analysis
Brexpiprazole significantly reduces agitation symptoms in Alzheimer's disease, as shown by improvements in CMAI and NPI-NH scores, with no significant cognitive or safety concerns. While promising, limitations include moderate heterogeneity and short follow-up durations. Future studies should focus on long-term effects, quality of life, and identifying optimal patient subgroups for treatment.
Authors
- Marah Aqeel
- Hammad Javaid (ORCID: https://orcid.org/0009-0002-8938-0435)
- Anurag Jha
- Mahnoor Arfan
- Shamikha Cheema
- Muhammad Nabeel Saddique
- Meeram Noor
- Ayaan Musani
- Umaima Cheema
Institutions
- King Edward Medical University (PK)
- Pakistan Academy of Sciences (PK)
- Wilfrid Laurier University (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70858_103458
- Primary Topic
- Healthcare Decision-Making and Restraints
- Type
- article
- Field-Weighted Citation Impact
- 0.00